N-((3-Morpholinopyridin-4-yl)methyl)-6-(4-chlorophenyl)-pyrazine-2-carboxamide

ID: ALA1277792

Chembl Id: CHEMBL1277792

PubChem CID: 52948416

Max Phase: Preclinical

Molecular Formula: C21H20ClN5O2

Molecular Weight: 409.88

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(NCc1ccncc1N1CCOCC1)c1cncc(-c2ccc(Cl)cc2)n1

Standard InChI:  InChI=1S/C21H20ClN5O2/c22-17-3-1-15(2-4-17)18-12-24-13-19(26-18)21(28)25-11-16-5-6-23-14-20(16)27-7-9-29-10-8-27/h1-6,12-14H,7-11H2,(H,25,28)

Standard InChI Key:  XODADHNSUQUULV-UHFFFAOYSA-N

Associated Targets(Human)

SCN10A Tclin Sodium channel protein type X alpha subunit (396 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Scn10a Sodium channel protein type X alpha subunit (95 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 409.88Molecular Weight (Monoisotopic): 409.1306AlogP: 2.96#Rotatable Bonds: 5
Polar Surface Area: 80.24Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 12.74CX Basic pKa: 5.47CX LogP: 2.03CX LogD: 2.03
Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.70Np Likeness Score: -1.73

References

1. Scanio MJ, Shi L, Drizin I, Gregg RJ, Atkinson RN, Thomas JB, Johnson MS, Chapman ML, Liu D, Krambis MJ, Liu Y, Shieh CC, Zhang X, Simler GH, Joshi S, Honore P, Marsh KC, Knox A, Werness S, Antonio B, Krafte DS, Jarvis MF, Faltynek CR, Marron BE, Kort ME..  (2010)  Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.,  18  (22): [PMID:20965738] [10.1016/j.bmc.2010.09.057]

Source